用于阿尔茨海默氏症治疗的药物通过调整乳酸相互作用蛋白来重新定位
Xin Liu1, Jun-He Cui1, Chuang Luan1
1Key Laboratory of Bioresource Research and Development of Liaoning Province, College of Life and Health Sciences, Northeastern University, Shenyang 110169, China.
International journal of biological macromolecules
|May 16, 2025
概括
研究人员确定了用于阿尔茨海默病 (AD) 的新药重定向候选人. 洛瓦斯塔丁,SU-11652和SB-239063通过向乳酸铁素 (Ltf) 和减少粉样β生产,显示出潜在的潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 是一个重大挑战,治疗目标有限.
- 乳酸 (Ltf) 是一种潜在的生物标志物和阿尔茨海默病的治疗点,但研究很少.
- 药物重新利用为发现新的AD治疗提供了一个有希望的途径.
研究的目的:
- 通过药物重定向以向乳二 (Ltf) 来确定AD的潜在治疗剂.
- 探索Ltf的相互作用和调节网络,用于药物发现.
主要方法:
- 计算药物重定向策略,包括互动组分析和途径丰富.
- 分子对接,表面等离子体共振 (SPR),体内研究和免疫光分析.
- 在体外对N2a-sw细胞进行研究,以评估对β-粉样蛋白 (Aβ) 生产和酶表达的影响.
主要成果:
- 确定了三个候选药物:洛瓦斯塔丁,SU-11652和SB-239063,具有强烈的与Ltf.结合的亲缘关系.
- 证明这些药物通过调节Ltf光和amyloidogenic通路酶 (BACE1,APH1α) 在体外减少Aβ的产生.
- 在体内观察到BACE1或APH1α表达水平的降低.
结论:
- 洛瓦斯塔丁,SU-11652和SB-239063是阿尔茨海默病的有希望的重用药物.
- 向Ltf相互作用为AD药物重新定位提供了一个可行的策略.
- 这些发现支持对阿尔茨海默病的Ltf向疗法的进一步研究.
更多相关视频
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
9.2K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.8K
相关概念视频
01:22Alzheimer's Disease: Treatment
142
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
142
01:26Alzheimer's Disease: Overview
412
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
412
01:22Lysosomal Hydrolases
3.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.7K